PRIMARY STUDY
Micronized Palmitoylethanolamide-Polydatin Reduces the Painful Symptomatology in Patients with Interstitial Cystitis/Bladder Pain Syndrome
Key Findings: In this study micronized-palmitoylethanolamide-polydatin (m-PEA-Pol) was effective in reducing pain and urinary frequency associated with treatment-resistant cystitis and bladder pain syndromes. It had a less than significant increase in bladder capacity
Type of Study: Clinical Trial
Study Sample Size: 32
Study Result: Positive
Research Location(s): Italy
Year of Pub: 2019
Cannabinoids Studied: Palmitoylethanolamide (PEA)
Phytocannabinoid Source: Not Applicable
Receptors Studied: GPCR 55, TRPV1, PPARs
DOSING DETAILS 
Study Dosing Objective: Effective Dose
Established Protocol: Effective dose
Route of Administration: Oral (Ingestion)
Dosing Regimen: 400 mg m-PEA plus 40 mg polydatin
Adverse Events: None of the participants reported adverse events
Citation: Cervigni M, et al. Micronized Palmitoylethanolamide-Polydatin Reduces the Painful Symptomatology in Patients with Interstitial Cystitis/Bladder Pain Syndrome. Biomed Res Int. 2019; 2019:9828397. doi: 10.1155/2019/9828397
Authors: Cervigni M, Nasta L, Schievano C, Lampropoulou N, Ostardo E
